COOK Medical and EnteraSense Ltd have entered into a new agreement that will see Cook become the exclusive distributor of EnteraSense’s PillSense product in the United States.
The Castletroy-based Cook will begin assuming sales management and marketing responsibilities for the product towards the end of 2024. This distribution agreement is a new way for Cook to collaborate with other companies and do business, empowering Cook to offer the innovative PillSense technology to Cook customers.
PillSense is a novel blood-sensing system, a statement on behalf of the companies said. After a patient swallows the PillSense capsule, it can accurately detect upper gastrointestinal bleeding.
The system allows for fast diagnosis and appropriate triaging of patients with suspected gastrointestinal bleeding. The US Food and Drug Administration (FDA) approved PillSense in February 2023.
“Gastrointestinal bleeds can be life-threatening. The sooner physicians can diagnose a bleed, the better chance a patient has of survival,” said Meurisse Leahy, director of product management for Cook’s endoscopy specialty.
“Physicians can combine PillSense with our Hemospray and Instinct Plus products to both diagnose and treat gastrointestinal bleeds faster. Through this distribution partnership, we’re excited to expedite delivery of this unique product to healthcare providers.”
“The innovative PillSense system can transform how UGIB (upper gastrointestinal bleed) patients are diagnosed and deliver significant benefits to patients, clinicians, and hospitals. This strategic partnership between EnteraSense and Cook Medical will accelerate the availability of PillSense right across the US,” added Donal Devery, EnteraSense CEO.
Cook’s partnership with EnteraSense is the third distribution agreement the company has entered into in 2024, having previously in March agreements with Bentley’s BeBack Catheter and Getinge’s iCast covered stent system.
